Q1 Earnings Estimate for ENSC Issued By Zacks Research

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Investment analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for shares of Ensysce Biosciences in a report issued on Tuesday, March 31st. Zacks Research analyst B. Sorensen expects that the company will earn ($0.73) per share for the quarter. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($3.54) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Ensysce Biosciences Stock Performance

ENSC stock opened at $0.55 on Thursday. Ensysce Biosciences has a fifty-two week low of $0.31 and a fifty-two week high of $4.85. The business’s 50-day moving average is $0.54 and its two-hundred day moving average is $1.32. The company has a market cap of $1.99 million, a price-to-earnings ratio of -0.13 and a beta of 1.12.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.51. The firm had revenue of $1.88 million for the quarter, compared to the consensus estimate of $0.50 million. Ensysce Biosciences had a negative return on equity of 458.65% and a negative net margin of 200.87%.

Institutional Investors Weigh In On Ensysce Biosciences

Hedge funds have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. raised its holdings in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares during the period. DRW Securities LLC increased its position in Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after buying an additional 29,336 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Ensysce Biosciences in the third quarter worth about $34,000. Virtu Financial LLC bought a new position in shares of Ensysce Biosciences in the third quarter worth about $34,000. Finally, TRU Independence Asset Management 2 LLC purchased a new position in shares of Ensysce Biosciences during the 3rd quarter valued at about $25,000. Institutional investors own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.